AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02556814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeic acid tablets
Description: Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
Study NCT02556814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
Study NCT02556814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
Study NCT02556814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Oral administration of placebo tablets 0.3g three times per day for 3 months
Study NCT00652405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 250 ml of white wine (13% vol; \~25 gram of alcohol per day)
Study NCT00652405 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 ml of mineral water (Brand name: Vittel)
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily with or without food
Study NCT02101060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 16-week progressive aerobic and resistance exercise training
Study NCT02269241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LF111 (drospirenone)
Description: One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
Study NCT04229394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2ccPA
Description: Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1
Study NCT04229394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1
Study NCT02254486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NER1006
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study NCT02254486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trisulfate solution
Description: The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Study NCT03556150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy protocol
Description: This protocol consists of:~* Six minutes of joint's mobilisation (two minutes of each technique).~* Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~* Three minutes of trigemino's nerve stretching.
Study NCT03556150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effleurage
Description: The protocol consists of:~* Five minutes in temporal muscle.~* Ten minutes superficial massage in the neck and cheek of the most painful joint.~* Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside.
Study NCT02254187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol capsule - low
Study NCT02254187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol capsule - high
Study NCT02254187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol via Serevent® Diskus®
Study NCT01427504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir; etravirine
Description: boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 \& 30
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks.
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Description: PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks.
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks.
Study NCT03495960 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
Study NCT03495960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Injection administered subcutaneously once every 2 weeks
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food
Study NCT01885195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
Study NCT04204291 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
Study NCT03277118 — intervention group
Intervention type: DEVICE
Intervention: Wireless Wearable Device
Description: Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
Study NCT04362839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT04362839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04362839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT04544449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenebrutinib
Description: Participants will receive fenebrutinib.
Study NCT04544449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Participants will receive ocrelizumab.
Study NCT04544449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to ocrelizumab
Description: Participants will receive ocrelizumab-matching placebo.
Study NCT04544449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matched to fenebrutinib
Description: Participants will receive fenebrutinib-matching placebo
Study NCT04492033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009 (ABL001)
Description: CTX-009 (ABL001) will be administered biweekly.
Study NCT04492033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered weekly.
Study NCT04492033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered biweekly.
Study NCT03566043 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-121
Description: Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
Study NCT02542605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered once on day 1 of Part B of the study by intravenous infusion.
Study NCT02542605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once on day 1 of Part B of the study by intravenous infusion.
Study NCT02542605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACAP-38 Challenge Agent
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Study NCT02263989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan film coated tablet
Study NCT02263989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan conventional tablet
Study NCT02811250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 4 x 8 Gy
Study NCT02811250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 5 x 8 Gy
Study NCT02811250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 4 x 10 Gy
Study NCT02811250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy 4 x 12 Gy
Study NCT02542605 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PACAP-38 Challenge Agent
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Study NCT02542605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PACAP-38 Challenge Agent
Description: Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.
Study NCT04239820 — intervention group
Intervention type: RADIATION
Intervention: Imaging
Description: MRI and TSPO-PET imaging at baseline and 18 months after baseline
Study NCT04135326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04135326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05568082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral tablet
Study NCT05568082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral capsule
Study NCT04135326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Undergo tDCS
Study NCT02730026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
Study NCT02730026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen and Omeprazole
Description: Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
Study NCT04420078 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter Ablation
Description: Ventricular fibrillation substrate
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) Two-day sampling
Description: Collect two stool samples in two separate days
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) One-year interval
Description: Screening with one-year interval
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablets administered orally once daily with or without food
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Injection administered subcutaneously once every 2 weeks
Study NCT04115748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match adalimumab
Description: Injection administered subcutaneously once every 2 weeks
Study NCT00654745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg tablets , Daily for 3 weeks;
Study NCT00654745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine / olmesartan medoxomil combination
Description: amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
Study NCT00654745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: hydrochlorothiazide tablets, 12.5 mg or 25 mg.
Study NCT01390831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERMOCOOL® Catheter
Description: Catheter-based renal denervation
Study NCT04685720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LungFit
Description: LungFit for NTM is an experimental device that produces Nitric Oxide from the ambient air.
Study NCT04176991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTI-1601
Description: CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
Study NCT04176991 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT(Eiken OC-Sensor) One-day sampling
Description: One-day sampling
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIT(Eiken OC-Sensor) One-day sampling
Description: One-day sampling
Study NCT03291054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
Study NCT03291054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
Study NCT00648427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
Description: 25mg, single dose fasting
Study NCT00648427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR™ Tablets 25 mg
Description: 25mg, single dose fasting
Study NCT04043455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 1 capsule or tablet by mouth, 3 times per day up to 12 weeks
Study NCT04043455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 12 weeks
Study NCT04043455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 12 weeks
Study NCT04043455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olorinab matching placebo capsule or tablet by mouth, 3 times per day up to 12 weeks
Study NCT04043455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 2 capsule or tablet by mouth, 3 times per day up to 52 weeks
Study NCT04043455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab Dose 3 capsule or tablet by mouth, 3 times per day up to 52 weeks
Study NCT02079740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02079740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT02079740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo conventional CT or PET/CT
Study NCT02079740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02079740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: Given PO
Study NCT02079740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT02079740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT01741363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIT(Eiken OC-Sensor) Two-year interval
Description: Screening with two-year interval
Study NCT01591837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Influenza Vaccine
Description: The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
Study NCT05066503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 260279 active study product
Description: The active study product (20g per serving) contains 13.6g of amino acids and natural flavors, citric acid, malic acid, and stevia for flavoring.
Study NCT02807129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood withdrawn
Study NCT02807129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine collection
Study NCT03422822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: In the initial treatment period, Abrocitinib 100 mg, administered as two tablets to be taken orally once daily.
Study NCT03422822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Description: In the initial treatment period, Abrocitinib 200 mg, administered as two tablets to be taken orally once daily.
Study NCT03422822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For subjects whose dose was changed from 100 mg Abrocitinib to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
Study NCT03422822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Description: For subjects whose dose was changed from 200 mg Abrocitinib to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.